Agenda

When faced with a new product that can be transformational to the field, the key issue becomes understanding the adoption dynamics, identifying the drivers of change within this dynamic, and then building a plan to deliver on transforming the adoption cycle.

Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them

The audience can expect to be able to participate actively in the “conversation” and contribute to the program.

One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:

1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion

In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.

With over 30 years at the “sharp-end” of intelligence gathering across the world, one the Co-Founder(s) of Dig Worldwide will provide plenty of real-life anecdotes and experiences. Dig Worldwide’s talk will briefly cover the following:
• Legal and ethical frameworks
• The six techniques that aid competitor-based communications
• Suggestions on how to protect your competitive advantage in the office and other public venues from companies such as Dig Worldwide

The EMA follows various procedural timetables to evaluate potential marketing authorisations, which differ in length and requirements from the US FDA and other agencies. We will present data to help you more accurately predict approval timelines and discuss how this can be supplemented by CI insights to better understand competitors’ launch strategy.

How can we use demographic shifts to help inform new business models? How will digital disruption affect drug development and access? How are mHealth platforms shifting patients’ approaches to healthcare?

Specifically this presentation will enable you to:

* Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
* Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
* Understand Gx / biosimilar product development and entry strategies
* Identify potential actions to optimize launches

A result of this can be dissatisfied end users and low utilization rates. Understanding the value proposition disconnect and developing strategies to better align the two value propositions can improve both patient and sales outcomes.

This session will describe how Win/Loss for the LS market can generate new insights into intermediate and end user decision factors and demonstrate how to adjust the value proposition to improve the match for both end user and purchase decision maker. With a particular emphasis on drug formulary, delivery systems, surgical devices, and medical imaging products, the session will discuss how to design a Win/Loss program for LS, how to interpret Win/Loss findings for strategy development, and how a Win/Loss program of LS differs from typical Win/Loss programs.
Session attendees will gain a deeper understanding of how Win/Loss can apply to LS and drive strategy. Real world (blinded) examples of Win/Loss components (questionnaires, interview excerpts, and analysis reports) will be presented to illustrate the different tools and benefits of a Win/Loss program.

If biopharma companies want to expand in these emerging areas, their strategy must be tailored to the developing pace of change. We will discuss the most promising emerging areas, to lay out the opportunities, challenges and trends that will drive change and explain how CI can help steer organizational strategic success.